Isotroin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isotroin

Quick Facts

Property Description
Active Ingredient Isotretinoin (13-cis-retinoic acid)
Form Soft gel capsules (Oral administration)
Pharmacological Class Retinoid, Systemic Anti-Acne Agent
General Purpose Foundational treatment for severe, resistant conditions
Origin Synthetic, Vitamin A Derivative

What Type of Medicine is Isotroin? (Identity and Classification)

Isotroin is a prescription-only medicine containing the active component Isotretinoin, which is classified as a potent systemic anti-acne agent belonging to the Retinoid class of drugs. This brand is presented as soft gel capsules for oral administration. The medicine’s status as a systemic agent means that it is intended for widespread, internal action, distinguishing it from products limited to topical application. Isotretinoin is utilized for severe skin conditions that have not been adequately controlled by other medications. This treatment is intended to profoundly modify skin function, solidifying its place as a definitive dermatological tool.

Isotretinoin: A Synthetic Vitamin A Derivative (Composition and Origin)

The core component, Isotretinoin, is a synthetic derivative of Vitamin A, specifically the 13-cis-retinoic acid isomer, which possesses a highly targeted action profile. As a single-ingredient product, the formulation uses an oil-based vehicle encapsulated in the oral capsule, a specific design chosen to enhance the absorption of the lipid-soluble active compound into the bloodstream for efficient systemic distribution. While other brands like Roaccutane or Accutane use the same active substance, Isotroin is often positioned as an accessible option for patients requiring intensive regulation of skin cell processes.

General Purpose of this Systemic Treatment (High-Level Benefit)

The overarching purpose of this systemic retinoid is to deliver comprehensive skin clearing action by modulating the fundamental biological causes of chronic skin issues. Its primary therapeutic benefit arises from two high-level principles: initiating a significant reduction of sebum production by the sebaceous glands and promoting the normalization of skin cell growth to prevent the primary formation of pore blockages. By addressing these core internal processes, Isotroin offers a foundational and potent intervention for managing severe, resistant conditions, particularly in adult and adolescent patient groups.

Regulatory References

  1. U.S. National Library of Medicine
  2. MedlinePlus Drug Information

What side effects are possible with Isotroin?

Possible side effects and safety information

The safety profile of Isotroin (isotretinoin) is defined by its systemic retinoid effects and critical safety constraints established by regulatory authorities. The adverse reactions are formally classified by frequency and system-organ class.

Frequency-Classified Adverse Reactions

The most frequently observed effects are related to the skin and mucous membranes, categorized as Very Common (affecting more than 1 in 10 users). These include cheilitis (lip inflammation), dry skin, dryness of mucous membranes, epistaxis (nosebleeds), headache, arthralgia (joint pain), and back pain. Laboratory findings often show very common, reversible elevations in liver transaminases and blood triglycerides.

Uncommon reactions include allergic responses, depression, anxiety, and mood alteration. Rare but serious adverse reactions documented in official sources include reports of suicidal ideation and psychotic disorders, Inflammatory Bowel Disease (IBD), and severe skin reactions such as Stevens-Johnson Syndrome.

Regulatory Safety Constraints

The most critical safety constraint is the risk of severe teratogenicity (birth defects). Regulatory bodies mandate strict Pregnancy Prevention Programmes for women of childbearing potential, requiring mandatory contraception before, during, and after treatment. Isotroin is contraindicated in patients with severe hepatic impairment, pre-existing hypervitaminosis A, or uncontrolled hyperlipidemia. The medicine is also not to be used concurrently with tetracycline antibiotics due to the documented risk of elevated intracranial pressure.

Time-related patterns noted in official labeling include a common, usually transient, initial worsening of acne at the start of treatment. Skeletal changes like hyperostosis are often associated with long-term exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Isotroin (isotretinoin) overdose establishes that clinical presentations are consistent with signs of hypervitaminosis A (excessive systemic Vitamin A). Documented manifestations include severe headache, dizziness, nausea, vomiting, abdominal pain, irritability, and swelling or cracking of the lips. The most severe, documented clinical outcome is the potential for increased intracranial pressure (pseudotumor cerebri), a specific neurological risk requiring immediate monitoring.

Regulatory guidance explicitly mandates that any individual suspecting an overdose must seek emergency medical attention immediately, specifically by contacting the Poison Help line or local emergency services. The medication must be discontinued immediately upon presentation of overdose symptoms.

As documented, no specific antidote is known for Isotroin overdose, limiting treatment to symptomatic and supportive management. The official labeling specifies that stomach evacuation may be indicated in the first few hours. Furthermore, a critical, population-specific consideration requires that female patients of childbearing potential undergo a mandatory pregnancy test at the time of overdose and again one month later, due to the severe teratogenic risk.

Therapeutic Uses of Isotroin

What Isotroin Treats: Main Uses and Benefits

Isotroin (isotretinoin) is a prescribed treatment primarily used for the management of severe and persistent acne that has demonstrated a lack of adequate response to other standard treatments, such as topical therapies or oral antibiotics. The medication's main therapeutic application is focused on severe acne presentations, specifically nodular, cystic, or conglobate lesions.

The essential benefit provided is the significant reduction of deep-seated inflammation and the subsequent healing of existing blemishes, which helps reduce the potential for permanent scarring. This action supports long-term preservation of skin texture and appearance. Isotroin is indicated for patients with severe nodular acne, acne at a high risk of scarring, and acne that is considered refractory to typical medical management.


Quick Fact: Relief for Severe Acne Lesions

Eligibility and Restrictions for Use

Who can and cannot use Isotroin? — Official Regulatory Information

Isotroin (isotretinoin) use is governed by strict regulatory rules established by agencies like the FDA and EMA to manage its significant risks. The population eligible for use is generally non-pregnant patients 12 years of age and older.

Populations for Whom Use is Prohibited (Contraindicated)

  • Pregnancy: The drug is strictly contraindicated in patients who are pregnant or who may become pregnant due to an extremely high risk of severe, life-threatening birth defects. Patients must comply with a mandated Risk Evaluation and Mitigation Strategy (REMS), such as the iPLEDGE program, which requires monthly monitoring and the use of two forms of effective contraception for patients who can become pregnant.
  • Hypersensitivity: It is contraindicated in patients with a known allergy to isotretinoin or any of its components (e.g., parabens, soya bean oil in some formulations).
  • Severe Medical Conditions: Contraindications also apply to patients with severe hepatic impairment, uncontrolled high blood lipid levels (hyperlipidemia), and hypervitaminosis A.

Eligibility Limitations

  • Age: Use in children under 12 years of age or pre-puberty is not recommended, as safety and efficacy have not been established. For patients under 18, some jurisdictions require agreement from two independent prescribers.
  • Lactation: Use is not recommended while breastfeeding and for a defined period after stopping the medicine. Patients with conditions like kidney disease or a history of mental health disorders require careful assessment and close monitoring during therapy.

What should I know about interactions with other medicines?

The official regulatory profile for Isotroin (isotretinoin) is primarily structured around avoiding severe pharmacodynamic interactions and managing cumulative toxicity risks.

Formal Contraindications and Restrictions

Co-administration of Tetracycline antibiotics is strictly contraindicated due to the officially documented risk of developing Intracranial Hypertension (Pseudotumor Cerebri). This restriction applies to all medicines within the tetracycline class.

The concurrent use of Vitamin A supplements and all other retinoids must be avoided. Isotroin is a Vitamin A derivative, and combining these substances carries a high risk of additive toxic effects, leading to Hypervitaminosis A.

Interactions Requiring Caution

Caution is necessary when using other medicines that carry an independent risk of affecting bone health. This includes Phenytoin and Systemic Corticosteroids, as the combined use warrants close monitoring for potential skeletal abnormalities.

The official profile notes that Isotroin did not cause a clinically relevant change in the systemic exposure of Ethinyl Estradiol, a component of oral contraceptives. However, the herbal supplement St. John’s Wort may reduce the effectiveness of hormonal contraceptives, which is a critical consideration given the mandatory nature of the pregnancy prevention program.

For patients with pre-existing Liver Disease, caution is advised as altered clearance may increase the effects and toxicity of Isotroin. High alcohol consumption is also a noted factor that may contribute to elevated serum triglycerides during therapy.

Mechanism of Action

Pharmacodynamic Mechanism: Isotretinoin

The action of Isotroin (Isotretinoin) is systemic and begins with the modulation of gene expression within the skin's oil-producing structures.

Nuclear Receptor Modulation and Genetic Modulation

The drug's active form functions as an agonist for intracellular Retinoic Acid Receptors (RARs), primarily RAR-gamma. This binding modulates gene transcription, leading to changes in the fundamental functions of sebocytes and keratinocytes and altering their cellular behavior.

Targeted Sebaceous Gland Involution

Through this genetic modulation, the drug selectively induces apoptosis (programmed cell death) in the sebocytes of the oil glands. This mechanism causes the glands to shrink and functionally involute, resulting in a significant down-regulation of sebum output.

Follicular Differentiation Normalization

A related action corrects the abnormal differentiation of cells lining the hair follicle (keratinocytes). This restoration of normal cell shedding reduces the likelihood of follicular occlusion, affecting the earliest biological phase of lesion development.

Dosage and Administration Information

Guidelines for Use

Isotroin (isotretinoin) is administered as an oral treatment via soft gel capsules. The dosing and administration are based on specific clinical requirements to ensure proper use, as the product is not substitutable with all other isotretinoin formulations.


Dosage and Administration Schedule

Administration is generally initiated at a dose of mathbf0.5 mg/kg/day and maintained within a range of mathbf0.5 to 1 mg/kg/day. The total daily dose is typically administered in two divided doses; once-daily dosing is generally not recommended. For patients with very severe disease or extensive scarring, the dose may be adjusted up to a maximum of mathbf2 mg/kg/day.

Feature Administration Summary
Timing in relation to meals Capsules must be taken with food (a meal or snack) to maximize absorption of the active ingredient.
Preparation Capsules must be swallowed whole with a full glass of liquid; they must not be chewed, crushed, or sucked.
Missed Dose If a dose is missed, it should be skipped, and the patient must return to the regular schedule; a dose must never be doubled.

Treatment Course and Duration

A single course of therapy typically lasts mathbf15 to 20 weeks. If a second course is warranted by persistent or recurring severe acne, it is generally not initiated until at least two months have passed since the completion of the first course. The medicine is indicated for use in patients mathbf12 years of age and older. For patients with severe renal impairment, a lower starting dose, such as mathbf10 mg/day, is recommended.

Recent Clinical Evidence

Research evidence / Overview of studies for Isotroin

Evidence for use in Chronic Kidney Disease (CKD)

Research exploring Isotroin for people with Chronic Kidney Disease has primarily used Randomized Controlled Trials (RCTs) and pooled analyses. These studies was evaluated in populations of adults with CKD, including individuals with and without Type 2 Diabetes Mellitus. The research examined variables such as changes in the estimated kidney filtering rate (eGFR) and the amount of protein in the urine (UACR).

The findings from these studies describe patterns observed in the populations examined. Research observed differences in the rate of eGFR decline over long-term observation when compared to control groups. Studies reported that observed values of UACR generally trended lower in the group receiving the drug. Data show patterns related to potassium, where an increased number of higher-than-normal serum potassium measurements was observed in some studies compared to control groups.

Evidence for use in Type 2 Diabetes Mellitus (T2DM)

Isotroin was studied for Type 2 Diabetes Mellitus in large-scale RCTs and real-world observational cohort studies. Researchers monitored outcomes related to systemic or functional imbalance like levels of glycated hemoglobin (HbA1c) and also measured body weight. Studies reported measurements where HbA1c values generally trended lower in the drug-receiving groups compared to those in control groups over defined time intervals. Body weight measurements generally trended toward a decrease from baseline.

Evidence for use in Heart Failure (HF)

Research examined the use of Isotroin in conditions marked by functional limitations, specifically chronic heart failure (HFrEF and HFpEF). The outcomes monitored included patient hospitalization rates and cardiovascular events. The findings describe patterns observed in these studies where the frequency of the composite outcome (e.g., cardiovascular death or heart failure hospitalization) was monitored and reported in comparison to control groups. Observed measurements of cardiac stress biomarkers generally trended toward lower values in the drug-treated cohorts.

Research Limitations and Uncertainty

Across all indications, data for certain groups remain insufficient, such as people with very advanced stages of kidney decline. Long-term effects are not fully established regarding durability of these patterns over many years. Research has explored its role across various populations, but data for certain groups remain insufficient (e.g., children or adolescents). The research contributes to the broader evidence landscape, but data are still emerging for complex interactions with other medications, and evidence quality varies across studies, particularly in the observational settings.

Frequently Asked Questions (FAQ)

Common questions about Isotroin (FAQ)


Q: Why is Isotroin described as a drug of last resort in some forums?

Official information from health authorities describes the active ingredient in Isotroin as a treatment for severe skin conditions that have not been adequately controlled by other medications. Its potency and systemic action position it as a potent systemic intervention for severe cases.

Q: How is Isotroin different from other common treatments (high-level)?

Isotroin belongs to the retinoid class of drugs and is classified as a systemic anti-acne agent. This means its action is internal and throughout the body, which is a key distinction from topical or less potent oral treatments.

Q: How long does it usually take before I start seeing noticeable results from Isotroin?

The full treatment course typically lasts 15 to 20 weeks. Official documentation does not define a specific time frame for when noticeable improvement should be expected to begin. However, it is noted that a common, usually transient, initial worsening of the condition may occur at the start of therapy.

Q: Does Isotroin affect eyesight or night vision?

Official documents note rare reports of adverse reactions affecting the eyes, including blurred vision and changes in color vision. Night blindness is specifically noted in regulatory information. Visual disturbances are among the adverse reactions documented in official safety information.

Q: Why is sun exposure cautioned against for patients using Isotroin?

Official labeling notes that the drug can cause photosensitivity, which is an increased sensitivity to sunlight. Due to this potential effect, official labeling notes that sun exposure should be minimized.

Q: What is the general rate of success described in research studies for Isotroin?

Official documents describe the drug as a foundational and potent intervention for managing severe, resistant conditions. They do not provide a single, standardized general success rate number, as outcomes depend on the severity of the specific condition being treated and the duration of the course.

Q: Can men taking Isotroin safely father children?

Studies are consistent with the finding that the amount of the drug found in the semen of men taking Isotroin is extremely low. Official safety assessments do not suggest this amount poses a risk to the fetus if the partner is pregnant.

Q: Can Isotroin cause hair thinning or loss?

The official product information notes that hair thinning (alopecia) is listed as an uncommon adverse reaction. Adverse reactions are formally classified by frequency in regulatory documentation.

Q: What are the signs of a serious, but rare, allergic reaction to Isotroin?

Uncommon reactions noted in official information include allergic responses. Rare but serious adverse reactions documented include severe skin reactions like Stevens-Johnson Syndrome, which are characterized by fever, rash, and blistering.

Q: Is Isotroin considered a 'cure' for the condition it treats?

Official documents describe Isotroin as a treatment or systemic anti-acne agent used to manage chronic skin issues. The language used in regulatory and authoritative documents avoids the claim that the medicine is a permanent cure.

Q: What are the rules about getting cosmetic procedures (like waxing or tattoos) while on Isotroin?

Official regulatory documents advise against procedures like waxing, dermabrasion, and laser treatment during therapy and for a period after discontinuation. This caution is based on the risk of scarring and abnormal healing.

Q: Can Isotroin be taken with other prescription acne medications?

Concurrent use with other agents in the Retinoid class is strictly contraindicated. Official labeling also advises against the concurrent use of topical peeling agents (keratolytics) to prevent additive irritation.

Q: What is the general expectation for the condition after stopping Isotroin treatment?

Official documentation notes that if a second course is warranted by persistent or recurring severe acne, it should not be initiated until at least two months have passed since the completion of the first course. This waiting period allows for re-evaluation of the condition.

Q: Can Isotroin affect athletic performance or endurance?

The official list of very common side effects includes joint pain (arthralgia) and back pain. These conditions are noted in official labeling because they may affect the patient's ability to engage in movement and physical activity.

Q: Does Isotroin have any known interactions with over-the-counter pain relievers like ibuprofen?

Official regulatory documents list specific interactions that require caution, such as Phenytoin and Systemic Corticosteroids due to skeletal risks. However, common over-the-counter NSAID pain relievers like ibuprofen are not listed as a formal contraindication.

Q: Is it safe to drink alcohol in moderation while taking Isotroin?

High alcohol consumption is noted in official labeling as a factor that may contribute to elevated serum triglycerides during therapy. This caution is noted in regulatory information due to the drug’s potential effect on blood lipid levels.

Q: Do I need to change my diet while taking Isotroin?

The capsule form of the medicine is required to be taken with food (a meal or snack) to ensure that the active ingredient is absorbed effectively. Additionally, consumption of high amounts of alcohol is advised against due to risks related to blood lipid levels.

Q: Can Isotroin affect liver enzyme levels, and why is testing required?

Elevated liver transaminases are classified as a Very Common side effect. Regulatory bodies mandate monitoring to assess liver function before and during therapy, and to help monitor for rare, severe hepatic impairment.

Q: Are there any special considerations for teenagers taking Isotroin?

The medicine is approved for use in patients 12 years of age and older. Safety and efficacy have not been established in children under 12 years of age. Some jurisdictions require agreement from two independent prescribers for patients under 18.

Q: Can people with pre-existing conditions like diabetes use Isotroin?

Official research has been conducted in populations including those with Type 2 Diabetes Mellitus, where variables like blood sugar (HbA1c) were monitored. Contraindications apply to patients with severe hepatic impairment and uncontrolled high blood lipid levels, but not T2DM specifically.

Q: Are there any foods or drinks that should be completely avoided while taking Isotroin?

Vitamin A supplements and all other retinoids must be avoided due to the high risk of additive toxic effects. High alcohol consumption is noted as a risk factor to be avoided due to its potential effect on blood lipid levels.

Q: Is Isotroin safe for older adults or seniors?

Safety and efficacy have been established for use in patients 12 years of age and older. Official documents do not list specific data or cautions that restrict the drug's use in the senior population, though individual assessment is always necessary.

Q: What are the potential long-term side effects described in clinical trials?

Official labeling notes skeletal changes such as hyperostosis and premature epiphyseal closure as effects that are often associated with long-term exposure. These findings are described in the adverse reaction section of regulatory documents.

Q: What happens if Isotroin is stored outside of the recommended temperature range?

Isotroin must be stored at a controlled room temperature between 20°C and 25°C and must not be frozen. Storage outside of this specified range may impact the product's stability.

Q: Is Isotroin available generically under other names?

The active ingredient in Isotroin is Isotretinoin. This drug substance name is listed in official regulatory files and is used in other brand names and generic formulations of the medicine.

Q: Why is blood testing often required monthly during treatment?

Mandatory blood testing is required due to the risk of severe teratogenicity, which necessitates monthly pregnancy testing. Testing is also required to monitor for elevations in liver transaminases and blood triglycerides, which are common but reversible side effects.

Q: Is it important to take Isotroin at the exact same time every day?

Official documents require the total daily dose to be administered in two divided doses. Consistency in timing is relevant to maintain steady systemic exposure of the active ingredient. Following a missed dose, the patient is instructed to return to the regular schedule.

How should Isotroin be stored and disposed of?

Official Storage and Disposal for Isotroin Capsules

Isotroin (isotretinoin) capsules must be stored according to official regulatory specifications to maintain product stability and safety. The medication must be kept at controlled room temperature between 20°C and 25°C (68°F and 77°F) and must not be frozen.

It is required to store the capsules in the original container or a tightly closed container, protecting them from light, heat, and moisture. Always keep the medication out of the sight and reach of children.

Regarding disposal, regulatory guidance instructs patients not to dispose of unused or expired Isotroin via wastewater or household trash. Unused capsules should be returned to a medication take-back program or pharmacist. Additionally, individuals taking Isotroin must not donate blood during therapy and for one month following discontinuation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isotroin found in:

A-Z Index: